Your browser doesn't support javascript.
loading
Saving time in the radiotherapy procedures for COVID-19 pneumonia treatment. A single-institution experience
Bonet, M; Vázquez, S; García, E; Mira, M; Morales-Rull, J. L; Visus, M; Jové, D; Ripol, O; Solé, C; Gutiérrez, L.
Afiliación
  • Bonet, M; Hospital Universitari Arnau de Vilanova. Radiation Oncology Department. Lleida. Spain
  • Vázquez, S; Hospital Universitari Arnau de Vilanova. Radiation Oncology Department. Lleida. Spain
  • García, E; Hospital Universitari Arnau de Vilanova. Radiation Oncology Department. Lleida. Spain
  • Mira, M; Hospital Universitari Arnau de Vilanova. Radiation Oncology Department. Lleida. Spain
  • Morales-Rull, J. L; IRBLleida (Institut de Recerca Biomèdica de Lleida. Fundació Doctor Pifarré). Lleida. Spain
  • Visus, M; Hospital Universitari Arnau de Vilanova. Radiation Physics and Radioprotection Department. Lleida. Spain
  • Jové, D; Hospital Universitari Arnau de Vilanova. Radiation Physics and Radioprotection Department. Lleida. Spain
  • Ripol, O; Hospital Universitari Arnau de Vilanova. Radiation Physics and Radioprotection Department. Lleida. Spain
  • Solé, C; Hospital Universitari Arnau de Vilanova. Internal Medicine Department. Lleida. Spain
  • Gutiérrez, L; Hospital Universitari Arnau de Vilanova. Internal Medicine Department. Lleida. Spain
Clin. transl. oncol. (Print) ; 23(11): 2344-2349, nov. 2021. ilus, graf
Article en En | IBECS | ID: ibc-223428
Biblioteca responsable: ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
Background The use of low dose radiotherapy (LD-RT) for the treatment of COVID-19 pneumonia is supported by biological rationale for its immunomodulatory effect. Some institutions have started to treat these patients showing encouraging results. To shorten procedure times is crucial for the comfort of symptomatic patients receiving respiratory support and to optimize institutional facilities. Patients and methods At our institution, LD-RT is offered to hospitalized patients with COVID-19 pneumonia and signs of early cytokine-released syndrome on behalf of a multicenter study. We designed a coordinated process flow starting from the patient transfer to the simulation CT-scan (first-step), to the end of the LD-RT treatment (last step). The times spent on each step of the process flow were evaluated. Results Mean age of treated patients was 83 (72–91) years-old. The timing parameters of the first 10 consecutive patients were analyzed. Except for the first (dummy run), patients were managed from the first to the last step in a median of 38 min (25–58, SD 10.67). The most time-consuming sub-process was the contouring of the treatment volumes and dosimetry. Conclusions LD-RT is not only an encouraging option for COVID-19 pneumonia patients, but a convenient and feasible procedure if performed in a coordinated way by reducing procedure times (AU)
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Neumonía Viral / Radioterapia / Infecciones por Coronavirus Límite: Aged / Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 06-national / ES Base de datos: IBECS Asunto principal: Neumonía Viral / Radioterapia / Infecciones por Coronavirus Límite: Aged / Female / Humans / Male Idioma: En Revista: Clin. transl. oncol. (Print) Año: 2021 Tipo del documento: Article